Publications by authors named "Patrick A Ott"

Claim this Profile
A
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Eryn Blass, Derin B Keskin, Chloe R Tu, Cleo Forman, Allison Vanasse, Scott J Rodig, Patrick A Ott

Cell· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.
F Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, Srin Ranasinghe, Ana Lako, Patrick A Ott, Scott J Rodig

Cancer Immunol Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
Ethan Trim, Anita Giobbie-Hurder, Tamara A Sussman, David Liu, Megan Insco, Patrick A Ott

Pigment Cell Melanoma Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Karam Khaddour, Rizwan Haq, Elizabeth I Buchbinder, David Liu, Michael P Manos, Patrick A Ott

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
David A Braun, Giorgia Moranzoni, Vipheaviny Chea, Bradley A McGregor, Eryn Blass, Patrick A Ott

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, Sylvie Rottey, Patrick A Ott, Scott A Laurie

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Vaccines for Melanoma.
Can Cui, Patrick A Ott, Catherine J Wu

Hematol Oncol Clin North Am· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Anna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, Miklos C Fogarasi, Patrick A Ott

J Immunother Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Patrick A Ott

Cancer Discov· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni, Patrick A Ott

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.
Edward F Fritsch, Patrick A Ott

Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Patrick A Ott, Jeffrey F Scott

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Scott Ely

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew

Cancer Immunol Immunother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Joanna Baginska, Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Charlotte Abrecht, Patrick A Ott

Cancer Immunol Immunother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision cancer medicine: Concepts, current practice, and future developments.
Anders Edsjö, Louise Holmquist, Birgit Geoerger, Frédérique Nowak, Georgy Gomon, Patrick A Ott

J Intern Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
Elizabeth I Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, Patrick A Ott

Invest New Drugs· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigen-directed therapeutics in the clinic: where are we?
Lien Lybaert, Kris Thielemans, Steven A Feldman, Sjoerd H van der Burg, Cedric Bogaert, Patrick A Ott

Trends Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
Elizabeth I Buchbinder, Anita Giobbie-Hurder, Patrick A Ott

Invest New Drugs· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
Elizabeth I Buchbinder, Kathleen L Pfaff, Madison M Turner, Michael Manos, Olivia Ouyang, Patrick A Ott, Scott J Rodig

J Immunother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy.
Garrett S Dunlap, Daniel DiToro, Joel Henderson, Sujal I Shah, Mike Manos, Patrick A Ott

Nat Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in neoantigen-directed therapeutics.
Lien Lybaert, Steve Lefever, Bruno Fant, Evelien Smits, Bruno De Geest, Patrick A Ott

Cancer Cell· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases.
Jennifer E Yeh, Marilyn T Wan, Allireza Alloo, Nageatte Ibrahim, Ivan Buzurovic, Patrick A Ott

JAAD Case Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Patrick A Ott

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma.
Jennifer E Yeh, Marilyn T Wan, Allireza Alloo, Nageatte Ibrahim, Patrick A Ott

JAAD Case Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis